Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition

The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet